Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements - Schedule of Financial Instrument Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Warrant liability	$ 473
Level 1 [Member]
Warrant liability
Fair value of liabilities
Level 1 [Member] \| Asuragen [Member]
Contingent consideration
Level 1 [Member] \| RedPath [Member]
Contingent consideration
Level 2 [Member]
Warrant liability
Fair value of liabilities
Level 2 [Member] \| Asuragen [Member]
Contingent consideration
Level 2 [Member] \| RedPath [Member]
Contingent consideration
Level 3 [Member]
Warrant liability	473
Fair value of liabilities	2,054	7,514
Level 3 [Member] \| Asuragen [Member]
Contingent consideration	1,581	1,545
Level 3 [Member] \| RedPath [Member]
Contingent consideration		5,969
Reported Value Measurement [Member]
Warrant liability	473
Fair value of liabilities	2,054	7,514
Reported Value Measurement [Member] \| Asuragen [Member]
Contingent consideration	1,581	1,545
Reported Value Measurement [Member] \| RedPath [Member]
Contingent consideration		5,969
Fair Value Measurements [Member]
Warrant liability	473
Fair value of liabilities	2,054	7,514
Fair Value Measurements [Member] \| Asuragen [Member]
Contingent consideration	$ 1,581	1,545
Fair Value Measurements [Member] \| RedPath [Member]
Contingent consideration		$ 5,969